A unique NANO-ADC like TARGETED NANOSPHERE (TNS) platform with emerging product candidates that can significantly improve upon the delivery, safety and performance of both existing and developing cancer (and other) therapeutics, including ADCs

NanoValent Pharmaceuticals, Inc. (NanoValent/NVP) is a privately-held company, collaborating closely with Children’s Hospital Los Angeles (CHLA) as well as other US academic partners. NVP has developed a highly flexible platform technology best demonstrated by lead product NV103, now approaching IND status and clinical status in 2026.  Now seeking Series A finance in 2024 NVP possesses a highly experienced core management team with a proven track record of success, supported by a strong clinical and operational capability.